An open-label, two-stage Phase I/IIa dose escalation study of BT062 in metastatic triple receptor-negative breast cancer and in metastatic transitional cell carcinoma of the urinary bladder

Trial Profile

An open-label, two-stage Phase I/IIa dose escalation study of BT062 in metastatic triple receptor-negative breast cancer and in metastatic transitional cell carcinoma of the urinary bladder

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 06 Sep 2017

At a glance

  • Drugs Indatuximab ravtansine (Primary)
  • Indications Advanced breast cancer; Bladder cancer; Male breast cancer
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms INTRAIN-BB
  • Sponsors Biotest AG
  • Most Recent Events

    • 06 Sep 2017 This trial has been completed in Germany (End Date: 2017-08-04).
    • 23 Jun 2016 This trial was suspended in Germany according to the European Clinical Trials Database record.
    • 25 Apr 2014 Patient dosing has begun in this clinical trial, according to an ImmunoGen media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top